Tuesday: FDA panel reviews Merck's Ragwiteck

Share this article:

Merck's prescription allergy medication Ragwitek is going before the FDA Allergenic Products Advisory Committee tomorrow, and the panel's discussion documents indicate the under-the-tongue medication is not associated with serious safety concerns, reports Reuters.

An FDA approval would provide an alternative to injections doctors typically give for pollen and ragweed allergies.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters